Evaluation of physical function and its association with body composition, quality of life and biomarkers in cancer cachexia patients

被引:18
作者
Anderson, Lindsey J. [1 ]
Lee, Jonathan [1 ]
Mallen, Melissa C. [1 ]
Migula, Dorota [1 ]
Liu, Haiming [1 ,2 ]
Wu, Peter C. [3 ,4 ]
Dash, Atreya [5 ,6 ]
Garcia, Jose M. [1 ,2 ]
机构
[1] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA
[2] Univ Washington, Dept Med, Gerontol & Geriatr Med, Seattle, WA USA
[3] Vet Affairs Puget Sound Hlth Care Syst, Dept Surg, Seattle, WA USA
[4] Univ Washington, Dept Surg, Seattle, WA 98195 USA
[5] Vet Affairs Puget Sound Hlth Care Syst, Dept Urol, Seattle, WA USA
[6] Univ Washington, Dept Urol, Seattle, WA 98195 USA
基金
美国国家卫生研究院;
关键词
Cancer cachexia; Functional impairment; Stair climb; Energy expenditure; Muscle strength;
D O I
10.1016/j.clnu.2020.07.001
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background & aims: There are currently no approved treatments for cancer cachexia. One of the main barriers to developing a treatment for this indication is the lack of consensus on clinically important tools for assessing functional impairment in this setting. This issue is of critical importance because functional improvement is likely to be required for approval by regulatory agencies. This cross-sectional study aimed to evaluate various functional performance measures and establish their association with body composition, energy expenditure, biomarkers, and patient-reported quality of life (QOL). Methods: Physical function, body composition, energy expenditure, cytokines, testosterone, and patient reported QOL were compared between men with solid tumors with cachexia (CAC; N = 48), without cachexia (CNC; N = 48), and weight-stable patients without cancer (CON; N = 37). Receiver Operator Characteristic curves and multivariate regression were performed to identify functional impairment cut points and predictors of physical function, respectively. Results: Patients with CAC displayed lower total lean and appendicular lean mass, stair climb power (SCP), upper body strength, and bioavailable testosterone, and displayed higher energy expenditure than CNC or CON (p < 0.03); CAC showed lower handgrip, respiratory quotient, and appetite, and higher cytokines and fatigue than CON (p < 0.032). A cut-point of 336 Watts for SCP provided 78% sensitivity and 77% specificity for classification of CAC (p = 0.001); SCP also performed better than other measures tested when compared to CON-derived normatives. Upper body strength exhibited moderate sensitivity and specificity for classification of CAC (p < 0.02). Elevated relative energy expenditure and cytokines negatively predicted, and muscle mass positively predicted, various muscle strength outcomes. Conclusion: Stair climb power and upper body strength may have potential as discriminatory tests for functional impairment in patients with cancer cachexia. Published by Elsevier Ltd.
引用
收藏
页码:978 / 986
页数:9
相关论文
共 47 条
[1]   Grip Strength Cutpoints for the Identification of Clinically Relevant Weakness [J].
Alley, Dawn E. ;
Shardell, Michelle D. ;
Peters, Katherine W. ;
McLean, Robert R. ;
Dam, Thuy-Tien L. ;
Kenny, Anne M. ;
Fragala, Maren S. ;
Harris, Tamara B. ;
Kiel, Douglas P. ;
Guralnik, Jack M. ;
Ferrucci, Luigi ;
Kritchevsky, Stephen B. ;
Studenski, Stephanie A. ;
Vassileva, Maria T. ;
Cawthon, Peggy M. .
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2014, 69 (05) :559-566
[2]   Adipose tissue inflammation and cancer cachexia: Possible role of nuclear transcription factors [J].
Batista, M. L., Jr. ;
Peres, S. B. ;
McDonald, M. E. ;
Alcantara, P. S. M. ;
Olivan, M. ;
Otoch, J. P. ;
Farmer, S. R. ;
Seelaender, M. .
CYTOKINE, 2012, 57 (01) :9-16
[3]   Epidemiology of sarcopenia among the elderly in New Mexico [J].
Baumgartner, RN ;
Koehler, KM ;
Gallagher, D ;
Romero, L ;
Heymsfield, SB ;
Ross, RR ;
Garry, PJ ;
Lindeman, RD .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1998, 147 (08) :755-763
[4]   Measurement of fatigue in cancer, stroke, and HIV using the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) scale [J].
Butt, Zeeshan ;
Lai, Jin-shei ;
Rao, Deepa ;
Heinemann, Allen W. ;
Bill, Alex ;
Cella, David .
JOURNAL OF PSYCHOSOMATIC RESEARCH, 2013, 74 (01) :64-68
[5]   Muscle mass and association to quality of life in non-small cell lung cancer patients [J].
Bye, Asta ;
Sjoblom, Bjorg ;
Wentzel-Larsen, Tore ;
Gronberg, Bjorn H. ;
Baracos, Vickie E. ;
Hjermstad, Marianne J. ;
Aass, Nina ;
Bremnes, Roy M. ;
Flotten, Oystein ;
Jordhoy, Marit .
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2017, 8 (05) :759-767
[6]   Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non-small cell lung cancer or colorectal cancer: a randomized, double-blind, placebo-controlled, international multicentre phase II study (the ACT-ONE trial) [J].
Coats, Andrew J. Stewart ;
Ho, Gwo Fuang ;
Prabhash, Kumar ;
von Haehling, Stephan ;
Tilson, Julia ;
Brown, Richard ;
Beadle, John ;
Anker, Stefan D. .
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2016, 7 (03) :355-365
[7]   Inflammation and cancer [J].
Coussens, LM ;
Werb, Z .
NATURE, 2002, 420 (6917) :860-867
[8]  
Crawford J, 2014, SUPPORT CARE CANC, V2, pS30
[9]   Sarcopenia: European consensus on definition and diagnosis [J].
Cruz-Jentoft, Alfonso J. ;
Baeyens, Jean Pierre ;
Bauer, Juergen M. ;
Boirie, Yves ;
Cederholm, Tommy ;
Landi, Francesco ;
Martin, Finbarr C. ;
Michel, Jean-Pierre ;
Rolland, Yves ;
Schneider, Stephane M. ;
Topinkova, Eva ;
Vandewoude, Maurits ;
Zamboni, Mauro .
AGE AND AGEING, 2010, 39 (04) :412-423
[10]   ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia [J].
Currow, D. ;
Temel, J. S. ;
Abernethy, A. ;
Milanowski, J. ;
Friend, J. ;
Fearon, K. C. .
ANNALS OF ONCOLOGY, 2017, 28 (08) :1949-1956